A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies

Blood

Volumn 89, Issue 6, 1997, Pages 2089-2097

  Gidlöf, Cecilia ^b   Dohlsten, Mikael ^b   Lando, Peter ^b   Kalland, Terje ^b   Sundström, Christer ^b   Tötterman, Thomas H ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD34 ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; STAPHYLOCOCCUS ENTEROTOXIN A; SUPERANTIGEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; BINDING AFFINITY; CELL LINE; CHRONIC LYMPHATIC LEUKEMIA; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTER; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; IODINATION; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0030937256     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.6.2089     Document Type: Article

References (35)

1. Aisenberg AC: Coherent view of non-Hodgkin's lymphoma. J Clin Oncol 13:2656, 1995
2. Dillman RO: Antibodies as cytotoxic therapy. J Clin Oncol 12:1497, 1994
3. Sausville EA, Headlee D, Stetler-Stevenson M, Jaffe ES, Solomon D, Figg WD, Herdt J, Kopp WC, Rager H, Steinberg SM, Ghetie V, Schindler J, Uhr J, Wittes RE, Vitetta ES: Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A phase I study. Blood 85:3457, 1995
4. Amlot PL, Stone MJ, Cunningham D, Fay J, Newman J, Collins R, May R, McCarthy M, Richardson J, Ghetie V, Ramilo O, Thorpe PE, Uhr JW, Vitetta ES: A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 82:2624, 1993
5. Grossbard ML, Gribben JG, Freedman AS, Lambert JM, Kinsella J, Rabinowe SN, Eliseo L, Taylor JA, Blättler WA, Epstein CL, Nadler LM: Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood 81:2263, 1993
6. Uckun FM, Evans WE, Forsyth CJ, Waddick KG, Ahlgren L, Chelstrom LM, Burkhardt A, Bolen J, Myers DE: Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science 267:886, 1995
7. Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, Fisher DR, Porter B, Matthews DC, Gooley T, Bernstein ID: Phase II trial of 13II-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336, 1995
8. 131I]anti-B1 (anti-CD20) antibody. N Engl J Med 329:459, 1993
9. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327:1209, 1992
10. Tao M-H, Levy R: Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccin for B-cell lymphoma. Nature 362:755, 1993
11. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52, 1996
12. Marrack P, Kappler J: The staphylococcal enterotoxins and their relatives. Science 248:705, 1990
13. Fischer H, Dohlsten M, Lindvall M, Sjögren HO, Carlsson R: Binding of staphylococcal enterotoxin A to HLA-DR on B cell lines. J Immunol 142:3151, 1989
14. Mollick JA, Cook RG, Rich RR: Class II MHC molecules are specific receptors for staphylococcal enterotoxin A. Science 244:817, 1989
15. + T helper cells differing in kinetics and capacities to produce interleukin 2 and interferon-gamma can be defined by the Leu-18 and UCHL1 monoclonal antibodies. Eur J Immunol 18:1173, 1988
16. Fischer H, Dohlsten M, Andersson U, Hedlund G, Ericsson P-O, Hansson J, Sjögren HO: Production of TNF-α and TNF-β by staphylococcal enterotoxin A activated human T cells. J Immunol 144:4663, 1990
17. Dohlsten M, Lando PA, Hedlund G, Trowsdale J, Kalland T: Targeting of human cytotoxic T lymphocytes to MHC class II-expressing cells by staphylococcal enterotoxins. Immunology 71:96, 1990
18. + mononuclear leukocytes and freshly prepared leukemia cells. Cell Immunol 129:426, 1990
19. Wallgren A-C, Festin R, Gidlöf C, Dohlsten M, Kalland T, Tötterman TH: Efficient killing of chronic B-lymphocytic leukemia cells by superantigen-directed T cells. Blood 82:1230, 1993
20. Gidlöf C, Dohlsten M, Kalland T, Tötterman TH: Antibodies are capable of directing superantigen-mediated T-cell killing of chronic B lymphocytic leukemia cells. Leukemia 9:1534, 1995
21. Betley MJ, Mekalanos JJ: Nucleotide sequence of the type A staphylococcal enterotoxin gene. J Bacteriol 170:34, 1988
22. Abrahmsen L, Dohlsten M, Segren S, Björk P, Jonsson E, Kalland T: Characterization of two distinct MHC class II binding sites in the superantigen staphylococcal enterotoxin A. EMBO J 14:2978, 1995
23. Dohlsten M, Abrahmsen L, Björk P, Lando PA, Hedlund G, Forsberg G, Brodin T, Gascoigne NRJ, Förberg C, Lind P, Kalland T: Monoclonal antibody-superantigen fusion proteins: Tumor specific agents for T cell based tumor therapy. Proc Natl Acad Sci USA 91:8945, 1994
24. Dohlsten M, Lando PA, Björk P, Abrahmsen L, Ohlsson L, Lind P, Kalland T: Immunotherapy of human colon cancer by antibody-targeted superantigens. Cancer Immunol Immunother 41:162, 1995
25. Lennert K, Feller A: Histopathology of Non-Hodgkin's Lymphomas (ed 2). New York, NY, Springer-Verlag, 1992
26. Brugger W, Bross KJ, Glatt M, Weber F, Mertelsmann R, Kanz L: Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 83:636, 1994
27. Lando PA, Dohlsten M, Ohlsson L, Kalland T: Tumor-reactive superantigens suppress tumor growth in humanized SCID mice. Int J Cancer 62:466, 1995
28. Triozzi PL, Eicher DM, Smoot J, Rinehart JJ: Modulation of leukemic cell sensitivity to lymphokine-activated killer cytolysis: Role of intercellular adhesion molecule-1. Exp Hematol 20:1072, 1992
29. Dohlsten M, Hedlund G, Lando PA, Trowsdale J, Altmann D, Patarroyo M, Fischer H, Kalland T: Role of the adhesion molecule ICAM-1 (CD54) in staphylococcal enterotoxin-mediated cytotoxicity. Eur J Immunol 21:131, 1991
30. Stauder R, Greil R, Schulz TF, Thaler J, Gattringer C, Radaskiewicz T, Dierich MP, Huber H: Expression of leucocyte function-associated antigen-1 and 7F7-antigen, an adhesion molecule related to intercellular adhesion molecule-1 (ICAM-1) in non-Hodgkin lymphomas and leukaemias: Possible influence on growth pattern and leukaemic behaviour. Clin Exp Immunol 77:234, 1989
31. Horst E, Radaszkiewicz T, Hooftman-den Otter A, Pieters R, van Dongen JJM, Meijer CJLM, Pals ST: Expression of the leucocyte integrin LFA-1 (CD11a/CD18) and its ligand ICAM-1 (CD54) in lymphoid malignancies is related to lineage derivation and stage of differentiation but not to tumor grade. Leukemia 5:848, 1991
32. Rosendahl A, Hansson J, Sundstedt A, Kalland T, Dohlsten M: Immune response during tumor therapy with antibody-superantigen fusion proteins. Int J Cancer 67:1, 1996
33. Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES: Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice. Int J Cancer 45:481, 1990
34. Ihle J, Holzer U, Krull F, Dohlsten M, Kalland T, Niethammer D, Dannecker GE: Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines. Cancer Res 55:623, 1995
35. Holzer U, Bethge W, Krull F, Ihle J, Handgretinger R, Reisfeld RA, Dohlsten M, Kalland T, Niethammer D, Dannecker GE: Superantigen-staphylococcal-enterotoxin-A-dependent and antibody-targeted lysis of GD2-positive neuroblastoma cells. Cancer Immunol Immunother 41:129, 1995